Key Highlights

  • Cash, cash equivalents and marketable securities were USD 249.8 million at September 30, 2026, which the company believes will fund operations into the second half of 2029 under its current operating plans.
  • The third-quarter net loss widened to USD 32.4 million from USD 20.3 million a year earlier, as Research and Development rose to USD 22.0 million and general and administrative expense to USD 12.8 million.
  • A workforce reduction of approximately 46% was announced in September 2026 after the SION-719 add-on trial missed its key sweat chloride endpoint, with a placebo-adjusted change of minus 1.0 mmol/L.
  • The company plans to start the AscenSION CF Phase 2 proof-of-concept trial of SION-451 plus SION-2222 in the first quarter of 2027, with no product Revenue to date.

A Failed Add-On Trial Triggers a Restructuring

Sionna Therapeutics filed its Quarterly Report for the period ended September 30, 2026 on November 10, 2026. The company is a clinical-stage biopharmaceutical Business developing medicines for cystic fibrosis that stabilize a region of the CFTR protein called NBD1. In August 2026, its PreciSION CF Phase 2a trial of SION-719 as an add-on to Trikafta did not meet its key activity endpoint, showing a mean placebo-adjusted sweat chloride change of minus 1.0 mmol/L with a p-value of 0.7. The company does not plan to advance SION-719 as an add-on. In September 2026, it announced a workforce reduction of approximately 46% and other cost savings.

Spending Rose in the Quarter as Restructuring Costs Landed

Sionna Therapeutics (NASDAQ:SION) reported no revenue. Operating expenses for the third quarter were USD 34.8 million versus USD 23.8 million, and the loss from operations was USD 34.8 million. Research and development rose by USD 6.0 million, with direct program costs up USD 2.3 million on development work and the SION-719 wind-down, and personnel and restructuring costs also higher. General and administrative expense rose by USD 5.0 million, mostly personnel costs including restructuring. Interest income fell to USD 2.4 million from USD 3.5 million on lower balances. Nine-month net loss was USD 89.1 million against USD 54.8 million, and the accumulated Deficit was USD 345.4 million.

Pivot to a Dual Combination and the Funding Question

In August 2026, a Phase 1 trial of SION-451 in dual combinations met its safety, tolerability and pharmacokinetic objectives, and the company chose SION-451 with SION-2222 to advance. The planned AscenSION CF trial will be open-label, treat people for 28 days after switching from the standard of care, and measure sweat chloride, safety and pharmacokinetics. A post hoc analysis of the failed trial pointed to possible dosing non-adherence, lower Trikafta exposure and a potential drug interaction, which the company believes may have blunted the result. The company expects spending to fall near term, has a USD 250.0 million at-the-market program with no shares sold, and warned it will need substantial additional funding.

Where Things Stand

Management says the cash lasts into the second half of 2029, but the plan rests on a narrowed pipeline. Sionna Therapeutics (NASDAQ:SION) holds USD 249.8 million and expects to fund operations into the second half of 2029, yet that estimate rests on assumptions that may prove wrong. The quarterly loss of USD 32.4 million includes restructuring costs, and the company expects expenses to decrease near term. Next markers are the first-quarter 2027 start of AscenSION CF, the sweat chloride readout it is designed to produce, and any decision to use the at-the-market program.